Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530841 | 0.95 | SLC15A2 (0.39) | SLC15A2NTSR2NTSR1FURINC5AR1 | |
| SCHEMBL30296849 | 0.94 | SLC15A2 (0.38) | SLC15A2NTSR2NTSR1FURINC5AR1 | |
| SCHEMBL29531170 | 0.94 | SLC15A2 (0.39) | SLC15A2NTSR2NTSR1FURINC5AR1 | |
| SCHEMBL29799996 | 0.94 | SLC15A2 (0.44) | SLC15A2NTSR2NTSR1C5AR1 | |
| SCHEMBL30148442 | 0.93 | SLC15A2 (0.45) | SLC15A2NTSR2NTSR1C5AR1 | |
| SCHEMBL29014883 | 0.93 | SLC15A2 (0.42) | SLC15A2FURIN | |
| SCHEMBL31472587 | 0.93 | SLC15A2 (0.42) | SLC15A2FURIN | |
| SCHEMBL29653641 | 0.92 | SLC15A2 (0.50) | SLC15A2NTSR2NTSR1C5AR1NPY1R | |
| SCHEMBL29653685 | 0.92 | SLC15A2 (0.50) | SLC15A2NTSR2NTSR1C5AR1NPY1R | |
| SCHEMBL30600995 | 0.91 | SLC15A2 (0.39) | SLC15A2FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220249599-A1 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249599-A1 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | NGLY1, ANPEP, VIP | SLC15A2 662/4885NTSR2 539/4885NTSR1 378/4885 |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | SLC15A2 277/4885NTSR2 1145/4885NTSR1 792/4885 |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | SLC15A2 1479/4885NTSR2 1507/4885NTSR1 1108/4885 |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | SLC15A2 1479/4885NTSR2 1507/4885NTSR1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.